Victoza諾和力

Victoza

liraglutide

Manufacturer:

Novo Nordisk

Distributor:

Firma Chun Cheong
/
DKSH
Concise Prescribing Info
Contents
Liraglutide
Indications/Uses
Treatment of type 2 DM in combination w/ metformin or sulphonylurea in patients w/ insufficient glycaemic control despite maximal tolerated dose of monotherapy w/ metformin or sulphonylurea; in combination w/ metformin & sulphonylurea or thiazolidinedione in patients w/ insufficient glycaemic control despite dual therapy.
Dosage/Direction for Use
SC Initially 0.6 mg once daily for 1 wk, increase dose to 1.2 mg after a wk. Max: 1.8 mg/day.
Contraindications
Hypersensitivity. Type 1 DM, diabetic ketoacidosis; severe renal impairment & end-stage renal disease. Pregnancy & lactation.
Special Precautions
CHF, inflammatory bowel disease, diabetic gastroparesis, increased risk of pancreatitis, preexisting thyroid disease, risk of dehydration. Increased risk of hypoglycaemia w/ sulfonylurea. Hepatic impairment. Do not administer via IV or IM. May affect ability to drive or operate machinery. Childn <18 yr.
Adverse Reactions
GI disorders eg, nausea, diarrhoea, vomiting, dyspepsia, upper abdominal pain, constipation, gastritis, flatulence, abdominal distension, GERD, eructation; hypoglycaemia, anorexia, decreased appetite; headache; upper resp tract infection; inj site reactions.
Drug Interactions
May decrease Cmax & delay tmax of paracetamol, atorvastatin & OCs (ethinylestradiol, levonorgestrel). May increase Cmax of griseofulvin. May reduce AUC, decrease Cmax & delay tmax of digoxin & lisinopril.
MIMS Class
ATC Classification
A10BJ02 - liraglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.
Presentation/Packing
Form
Victoza pre-filled pen
Packing/Price
3 mL x 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in